10 May 2023 | News
Agreement aims to enable greater access to localised advanced testing capabilities for breast and lung cancer in more than 30 countries
Image credit: shutterstock
American multinational pharmaceutical and biotechnology corporation Pfizer and Thermo Fisher Scientific have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.
Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient.
Under the agreement, Thermo Fisher (an American supplier of scientific instrumentation, reagents and consumables, and software services) will identify local labs that will be using the company's NGS technology and ensure they have the necessary infrastructure, trained staff, and quality control measures to meet industry standards for NGS testing services for breast and lung cancer.
Pfizer will explore ways to enable affordable patient access for NGS testing for these types of cancer and work to raise healthcare provider awareness regarding the benefits of advanced testing. The two companies will continue to evaluate opportunities to expand geographically and to expand testing for other types of cancer.